N-hexyl-2,6-dideoxy-2,6-imino-D-glycero-D-galacto-heptitol | 1227834-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-hexyl-2,6-dideoxy-2,6-imino-D-glycero-D-galacto-heptitol
• 英文别名: (2R,3S,5S,6R)-1-hexyl-2,6-bis(hydroxymethyl)piperidine-3,4,5-triol
• CAS: 1227834-70-9
• 化学式: C₁₃H₂₇NO₅
• 分子量: 277.361
• InChiKey: FRSCBFYZDMYTCV-WYUUTHIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  104
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3,4,5,7-tetra-O-benzyl-N-hexyl-2,6-dideoxy-2,6-imino-D-glycero-D-galacto-heptitol 在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 水 、 溶剂黄146 为溶剂， 反应 48.0h， 以92%的产率得到N-hexyl-2,6-dideoxy-2,6-imino-D-glycero-D-galacto-heptitol
  参考文献：
  名称：

  Synthesis of N-substituted iminosugar derivatives and their immunosuppressive activities

  摘要：

  Several N-alkyl and hydroxyethyl-substituted iminosugar derivatives, including L-altro and D-galacto epimers, were synthesized and the effects of these synthetic iminosugars on proliferation of mouse splenocytes were evaluated in the MTT assay. The experimental data demonstrated that the N-alkylated D-galacto iminosugars showed better inhibitory activities than L-altro analogues, which might hold potential as immunosuppressive agents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2010.01.021

文献信息

• [EN] GLYCOSIDASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GLYCOSIDASES ET LEURS UTILISATIONS
  申请人：ALECTOS THERAPEUTICS INC

  公开号：WO2014032184A1

  公开（公告）日：2014-03-06

  The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

  该发明提供了用于抑制糖苷酶的化合物，这些化合物的前药，以及包括这些化合物或这些化合物的前药的药物组合物。该发明还提供了用于治疗与O-GlcNAcase缺乏或过度表达、O-GlcNAc的积累或缺乏相关的疾病和障碍的方法。
• GLYCOSIDASE INHIBITORS AND USES THEREOF
  申请人：Alectos Therapeutics Inc.

  公开号：US20150299122A1

  公开（公告）日：2015-10-22

  The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

  本发明提供了抑制糖苷酶的化合物，该化合物的前药，以及包括该化合物或该化合物的前药的制药组合物。本发明还提供了治疗与O-GlcNA酶的缺乏或过度表达、O-GlcNAc的积累或缺乏有关的疾病和障碍的方法。